BIOMARIN PHARMACEUTICAL INC Current Income Tax Expense (Benefit)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Current Income Tax Expense (Benefit) of $84.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC current income tax expense (benefit) for fiscal 2025 was $84.84M, a 44.27% increase from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC current income tax expense (benefit) for fiscal 2024 was $58.81M, a 10.76% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC current income tax expense (benefit) for fiscal 2023 was $65.90M, a 9.65% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC current income tax expense (benefit) for fiscal 2022 was $60.10M, a 1285.48% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $84.84M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $58.81M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $65.90M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $60.10M 10-K · filed 2025-02-24 | |
| 2021-12-31 | $4.34M 10-K · filed 2024-02-26 | |
| 2020-12-31 | -$13.03M 10-K · filed 2023-02-27 | -$12.52M 10-K · filed 2021-02-26 |
| 2019-12-31 | $11.80M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $2.88M 10-K · filed 2021-02-26 | |
| 2017-12-31 | $36.70M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $27.21M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $93.90M 10-K · filed 2018-02-26 | |
| 2014-12-31 | $34.72M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $8.76M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $5.99M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $5.85M 10-K · filed 2014-02-26 | |
| 2010-12-31 | $3.27M 10-K · filed 2013-02-26 | |
| 2009-12-31 | $1.05M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |